The blood–brain barrier can limit insulin transport into the CNS during the circumstances of hyperinsulinemia or insulin resistance [32, 57], which could reduce insulin’s neuroprotective effects despite systemic therapy. The gene discussed is INS; the disease is Insulin resistance.